Although vemurafenib appears to be safe and effective in pediatric patients with refractory or relapsed LCH associated with BRAF mutation, the data available in the literature are still limited, as most are based on case reports or case series. This evidence concerns the gene BRAF and Langerhans cell histiocytosis.